Compare State Street SPDR S&P Biotech ETF (XBI) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Materials Select Sector SPDR Fund — how do they compare? State Street SPDR S&P Biotech ETF trades at $153.85 (market cap $10.11B), while Materials Select Sector SPDR Fund trades at $49.43 (market cap $7.73B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Materials Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR S&P Biotech ETF for 38 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| XBI | XLB | |
|---|---|---|
Market Cap | $10.11B | $7.73B |
Volume | 12,903,266 | 13,681,146 |
Sector | Broad Market / Factor | — |
52-Week High | $169.55 | $53.67 |
52-Week Low | $104.99 | $42.23 |
Typical Hold Time | 38 Days | 70 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
XLB trades at $49.43, up 0.92% today, but technical indicators signal a bearish trend with moving averages and ADX showing sell signals. The ETF faces headwinds from sector concentration risks, with chemicals comprising 49% of assets. Recent news highlights materials as a potential 'anti-AI' play but questions near-term valuation after recent rebounds.
Outlook remains cautious given technical weakness and sector cyclicality. Investment opportunity exists for long-term infrastructure exposure, but risks include overconcentration in chemicals and potential earnings volatility. Current levels near support at $49 require monitoring for breakdown confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
